1. Home
  2. ELTX vs ALPS Comparison

ELTX vs ALPS Comparison

Compare ELTX & ALPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$1.90

Market Cap

63.3M

Sector

Health Care

ML Signal

HOLD

Logo ALPS Group Inc Ordinary Share

ALPS

ALPS Group Inc Ordinary Share

HOLD

Current Price

$0.33

Market Cap

66.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELTX
ALPS
Founded
2011
2017
Country
United States
Malaysia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.3M
66.6M
IPO Year
2014
2024

Fundamental Metrics

Financial Performance
Metric
ELTX
ALPS
Price
$1.90
$0.33
Analyst Decision
Buy
Analyst Count
4
0
Target Price
★ $13.67
N/A
AVG Volume (30 Days)
★ 258.8K
36.2K
Earning Date
11-12-2026
07-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 39.29
N/A
EPS
N/A
★ N/A
Revenue
★ $2,301,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.44
$0.23
52 Week High
$16.00
$1.72

Technical Indicators

Market Signals
Indicator
ELTX
ALPS
Relative Strength Index (RSI) 48.08 31.57
Support Level $1.74 $0.23
Resistance Level $1.97 $0.44
Average True Range (ATR) 0.15 0.02
MACD 0.04 -0.00
Stochastic Oscillator 79.63 5.26

Price Performance

Historical Comparison
ELTX
ALPS

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

About ALPS ALPS Group Inc Ordinary Share

ALPS Group Inc is an investment holding company involved in research and development, including stem cell and biotechnology-related business, and investing and managing businesses such as health and beauty centres and medical centres. The Company operates through Medical and Wellness, Life Science and Others segments. Medical and Wellness generates maximum revenue from non-surgical aesthetic services, surgical aesthetic services, medical consultation, health screenings, cellular therapy and research, and COVID-19 testing. Life Science provides whole-genome sequencing and pharmacogenomics, while Others comprises investment holding and provision of management services. The Company generates revenue in Malaysia.

Share on Social Networks: